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Purpose:  To  identify  if  recently  described  LOXL1  (lysyl  oxidase-like  1)  polymorphisms  are  associated  with
pseudoexfoliation glaucoma (XFG) in a United States (U.S.) Caucasian patient population.
Methods:  Individuals  with  XFG  were  identified  using  standard  clinical  examination  techniques.  TaqMan  allelic
discrimination assays were used to genotype 13 single nucleotide polymorphisms (SNPs) that tag LOXL1 in Caucasian
individuals. The coding region of exon 1 that includes the previously associated SNP, rs1048661, was sequenced. Allele
and genotype frequencies were compared between cases and unrelated controls.
Results: Fifty affected individuals and 235 control individuals were recruited into this study. We replicated the previously
reported association of three SNPs (rs1048661, rs2165241, and rs3825942) in our independent XFG population (single
SNP p-values were 0.001-0.02). The risk alleles at these three and several other intragenic SNPs are part of an extended
XFG-associated LOXL1 haplotype with a frequency of 32.0% in XFG patients and 21.6% in controls.
Conclusions: We have performed an analysis of LOXL1 and XFG in a United States patient population and have confirmed
the strong association previously reported for Icelandic and Swedish samples. However, due to the high frequency of risk
alleles in non-XFG individuals, this association should not form the basis of a diagnostic test for XFG. It is likely that
additional genetic or environmental factors modulate the penetrance of LOXL1 susceptibility alleles.
Pseudoexfoliation  syndrome  (XFS)  was  initially
described by Lindberg in 1917 [1] and further characterized
by Vogt in 1925 [2]. It is a systemic disorder in which an
unidentified, fibrillar substance is produced in abnormally
high  concentrations.  The  incidence  of  XFS  varies  among
ethnic  groups  [3]  with  incidences  of  20%–25%  in  the
Scandinavian  countries  of  Iceland  and  Finland  [4]  to  0%
reported in Greenland Eskimos [5]. The Framingham Eye
Study from the United States [6] revealed an overall incidence
in non-glaucoma individuals of 0.6% at the age of 52–64 years
that rose to 5.0% for 75–85-year-old individuals. Caucasians
over 60 years old in the United States have an incidence of
PEX  around  1.6%-3%  and  African-Americans  are
approximately 0.4% [7,8].
Both Lindberg [1] and Vogt [2] noted the association of
XFS with glaucoma and increasing age, and it is a major cause
of glaucoma throughout the world [3,9,10]. In general, the
incidence of glaucoma in XFS patients in the United States
appears to vary with the individual’s ethnic background. The
prevalence  appears  to  be  highest  among  individuals  with
Scandinavian ancestry and lower among African-Americans
[8,11]. The reported prevalence of XFG varies among ethnic
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groups and ranges from 0.4%-28% of open angle glaucoma
in the United States [8,11-13].
Recently, Thorleifsson et al. [14] performed a genome-
wide association study and identified a strong association of
XFG with three single nucleotide polymorphisms (SNPs) in
the lysyl oxidase-like 1 gene (LOXL1). They identified one
intronic SNP (rs2165241) and two nonsynonymous coding
SNPs (rs3825942 and rs1048661) with significant disease
association  in  Icelandic  and  Swedish  individuals.  This
association was recently replicated in both the midwestern
United States [15] and Australian [16] populations.
LOXL1 belongs to the “LOX” family of extracellular
enzymes that have multiple functions including the cross-
linking of collagen and elastin by oxidatively deaminating
lysine residues. Since XFS deposits are associated with the
extracellular and basement membrane regions, the LOX genes
are legitimate functional candidates to be involved with XFG
pathogenesis  [17].  There  are  five  such  enzymes  (LOX,
LOXL1, LOXL2, LOXL3, and LOXL4) that are involved
with  extracellular  matrix  metabolism.  LOXL1  has  been
implicated in the pathogenesis of spontaneous cervical artery
dissection [18] as well as bladder cancer [19].
METHODS
Patient ascertainment: This study adhered to the tenets of the
Declaration of Helsinki. The research protocol was approved
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146by the Duke University Institutional Review Board, and all
patients consented to participating in the study. All patients
were examined by board certified glaucoma specialists.
Pseudoexfoliation  changes  were  identified  as  the
presence of a central disk of XFS material, a clear annular
zone (partial or complete), or flakes of XFS material on the
lens surface, iris, or corneal endothelium in either eye. Patients
were excluded if there was a history of exposure to intense
infrared light, for example, glassblowing is associated with
true exfoliation of the lens capsule rather than XFS. XFG was
diagnosed  when  patients  possessed  the  above  XFS
characteristics and at least two of the following criteria: A)
documented intraocular pressure (IOP) ≥22 mmHg in either
eye; B) glaucomatous optic nerve cupping defined as a cup to
disc ratio >0.7 in either eye, notching of the neuroretinal rim,
or  an  asymmetric  cup  to  disc  ratio  >0.2;  and/or  C)
glaucomatous visual field loss consistent with the optic nerve
appearance.  Glaucoma  suspects  were  excluded  from  this
study. All cases and controls were Caucasian. Controls were
individuals of similar age as the patients without any evidence
of pseudoexfoliation deposits on intraocular tissues. Their
IOPs were in the normal range (<21 mmHg) with normal-
appearing optic nerves.
Single  nucleotide  polymorphism  selection  and  genotyping
methods: Blood samples were obtained from each individual
via peripheral venipuncture, and genomic DNA was isolated
using  standard  techniques  (Gentra,  Minneapolis,  MN).
Tagging SNPs for Caucasian individuals were selected using
Tagger in Haploview 3.32 with a pairwise r2 threshold of 0.8,
based on genotype data generated by the HapMap project. In
addition to tagging SNPs, we also genotyped the three specific
SNPs implicated by the previous study of XFG patients and
controls [14]. See Figure 1 for LOXL1 gene structure and
relative locations of SNPs used in this study. TaqMan allelic
discrimination  assays  were  performed  for  all  SNPs  per
standard  protocols  from  the  manufacturer  (Applied
BioSystems,  Foster  City,  CA).  Two  Centre  d'Étude  du
Polymorphisme Humain (CEPH) standards were included in
each 96-well plate for quality-control (QC), and samples from
six  individuals  were  duplicated  across  all  plates  with  the
laboratory technicians blinded to their identities. Genotype
submission to the analysis database required matching QC
genotypes  within  and  across  plates  and  at  least  95%
genotyping efficiency.
Sequencing:  All  sequencing  was  performed  using
appropriately selected primers and conditions optimized in a
standard fashion. The coding region of exon 1 that included
the SNP, rs1048661, was sequenced because a TaqMan assay
could not be designed. All sequencing was performed using
an ABI 3730 capillary sequencer (Applied BioSystems).
Statistical Analysis: Genotype frequencies of XFG cases and
controls  were  compared  by  logistic  regression  with
adjustment for age and sex using SAS software (SAS Institute
Inc., Cary, NC). Analysis of Hardy–Weinberg equilibrium
(HWE) was performed separately for cases and controls using
GDA software [20]. As in the original study by Thorleifsson
et  al.  [14],  SNP  genotypes  were  coded  according  to  a
multiplicative (log-additive) model in which the disease risk
in carriers of two variants is assumed to be the square of the
risk in carriers of a single variant. Haplotype analysis was
performed with the haplo.stats package [21,22].
RESULTS
Fifty XFG patients and 235 control individuals were recruited
into  this  study.  All  patients  (39  males-78%  and  11
females-22%)  and  controls  (145  males-61.7%  and  90
females-38.3%) were Caucasian. The mean age of diagnosis
was 74.0 (standard deviation,SD, was 8.0) years in patients;
the  age  at  recruitment  was  64.9  (SD  11.6)  years  for  the
controls.  All  SNPs  were  in  HWE  in  cases  (p>0.05)  and
controls (p>0.05). Table 1 presents the results of the logistic
regression  analysis  and  the  linkage  disequilibrium  (LD)
coefficients  (r2)  between  each  genotyped  SNP  and  the
previously  implicated  XFG  susceptibility  marker,
rs3825942 (G153D). We confirmed the previously reported
association  between  XFG  and  rs2165241  (p=0.001),
rs1048661 (p=0.02), and rs3825942 (p=0.02). Due to inter-
marker  LD,  several  other  intragenic  SNPs  also  showed
evidence of association at p≤0.02. The haplotype analysis of
SNPs, rs1048661 and rs3825942, confirmed that only three of
the four possible haplotypes were observed in our sample
(D’=1); the haplotype formed by the two protective alleles (T,
A) was not detected. However, the frequency of the high-risk
haplotype (G, G) in our population was lower than in the
Icelandic and Swedish populations (United States: 69.9% in
XFG cases, 46.6% in controls; Iceland: 81.4% in XFG cases,
49.8% in controls; and Sweden: 83.3% in XFG cases, 56.1%
in controls). A haplotype analysis of all 12 SNPs with minor
allele frequency (MAF)>5% confirmed that all individually
associated SNPs (p<0.05 in Table 1) were part of the same
XFG-associated haplotype, which had an estimated frequency
of 21.6% in controls and 32.0% in XFG patients (haplotype-
specific  p-value  was  0.03).  All  other  LOXL1  haplotypes
occurred  at  less  than  10%  frequency  in  controls.  This  is
Figure 1. LOXL1 gene structure with the position of each SNP as
indicated.
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147consistent with high pairwise D’ values between the coding
SNP,  rs3825942,  and  the  other  XFG-associated  markers
(D’>0.9) but relatively low r2 values (Table 1) due to different
allele frequencies.
The  two  coding  SNPs,  rs1048661  (R141L)  and
rs3825942 (G153D), were analyzed for their ability to predict
affection status. The rs1048661 SNP demonstrated a 95.7%
sensitivity (45 of 47 cases have the G allele) but only 13%
specificity (28 of 215 controls lack the G allele) as a diagnostic
test  for  XFG.  The  rs3825942  SNP  demonstrated  a  100%
sensitivity (49 of 49 cases have the G allele) but only 3.1%
specificity (7 of 225 controls lack the G allele).
DISCUSSION
Thorleifsson  et  al.  [14]  recently  reported  the  results  of  a
genome-wide association study of XFG that identified three
strongly associated LOXL1 sequence variants, two of which
were nonsynonymous coding SNPs. With this study, we have
replicated these associations in a U.S. population of XFG
patients and controls.
However, we demonstrate that these associations are not
strong enough to justify a diagnostic test for XFG. While the
rs1048661  and  rs3825942  SNPs  individually  have  high
sensitivity, their specificity is very poor (3.1% and 13.0%,
respectively)  due  to  their  high  prevalence  in  individuals
without  XFG.  This  same  high  prevalence  of  LOXL1  risk
alleles has been reported in all populations examined to date:
Nordic [14], midwestern United States [15], and Australian
[16]. This suggests that additional genes or environmental
factors  affect  the  penetrance  of  these  LOXL1  sequence
variants.  Further  investigation  of  the  complex  etiology  of
XFG is warranted.
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